Lars Erik Steinkjer, Nora Bratheim and Guro S. Kyrkjebø Nybø have contributed to the Norwegian chapter in the Chambers and Partners Life Sciences & Pharma IP Litigation 2025 Global Practice Guide.

Artificial intelligence (AI) is revolutionizing the way we perform tasks, from diagnosing patients to driving cars or answering exam questions. The increasing use of AI holds immense potential and can simplify and improve basic everyday tasks or those more important or critical. However, AI can also have unintended consequences.

Update on the implementation of the SPC manufacturing waiver for pharmaceutical manufacturers into Norwegian law.

Intellectual Property

Consumer, marketing and e-commerce

Data Protection and GDPR

Information Technology

Associate

Guro works mainly with questions related to intellectual property and data protection. She offers legal advice to clients in matters relating to e.g. patents, trademarks, trade secrets and GDPR, and also regularly contributes to due diligence processes.

Guro is particularly interested in intellectual property and data protection, and completed an LL.M. in Intellectual Property and Information Law at King's College London in 2022.

Oslo

{"title":{"title":"Guro S. Kyrkjebø Nybø | Wikborg Rein"}}

Guro works mainly with questions related to intellectual property and data protection.

Jump to main content

Articles on wr.no

Norwegian Chapter in the Chambers Life Sciences & Pharma IP Litigation 2025

Who is liable when the use of AI leads to harm?

SPC manufacturing waiver has entered into force in Norway